Lista de obras -

2012 focused update of the ESC Guidelines for the management of atrial fibrillation ⬇️

artículo científico publicado el 24 de agosto de 2012

A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

scientific article published on 11 November 2019

Aborted myocardial infarction: a new target for reperfusion therapy

artículo científico publicado en 2006

Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012

Anticoagulants in heart disease: current status and perspectives

artículo científico publicado en 2007

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

artículo científico publicado en 2018

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.

artículo científico

Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial

artículo científico publicado en 2015

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

artículo científico publicado en 2010

Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial

artículo científico publicado en 2013

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

artículo científico publicado en 2013

Apixaban with antiplatelet therapy after acute coronary syndrome

artículo científico publicado en 2011

Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis

artículo científico publicado en 2014

Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation

artículo científico publicado en 2003

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology

artículo científico publicado en 2011

Cardioversion as bystander in atrial fibrillation-related thrombo-embolism

artículo científico publicado en 2019

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

artículo científico publicado en 2016

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.

artículo científico publicado en 2016

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

artículo científico

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition

artículo científico publicado en 2015

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

artículo científico

Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)

artículo científico publicado en 2003

GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke

artículo científico publicado en 2020

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

artículo científico publicado en 2013

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

artículo científico publicado en 2008

Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention

Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction

artículo científico publicado en 2013

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

scientific article published on 01 April 2019

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

scientific article published on 01 July 2019

Low myocardial protein kinase G activity in heart failure with preserved ejection fraction

artículo científico publicado en 2012

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

artículo científico publicado en 2014

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.

artículo científico publicado en 2016

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper

artículo científico publicado en 2012

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis

artículo científico publicado en 2020

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

artículo científico publicado en 2016

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab

artículo científico publicado en 2003

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

scientific article published on 22 November 2018

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

scientific article published on 20 December 2019

Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial

artículo científico publicado en 2017

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

artículo científico publicado en 2016

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

scientific article published on 30 December 2019

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular

artículo científico publicado en 2015

Rivaroxaban Plasma Levels and Levetiracetam

artículo científico publicado en 2020

Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials

scientific article published on 19 June 2019

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations

scientific article published on 31 December 2018

The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial

artículo científico publicado en 2007

Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

scientific article published on 14 November 2013

Lista de obras de

2012 focused update of the ESC Guidelines for the management of atrial fibrillation ⬇️

A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

Aborted myocardial infarction: a new target for reperfusion therapy

Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012

Anticoagulants in heart disease: current status and perspectives

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.

Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

Apixaban with antiplatelet therapy after acute coronary syndrome

Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis

Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology

Cardioversion as bystander in atrial fibrillation-related thrombo-embolism

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)

GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention

Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

Low myocardial protein kinase G activity in heart failure with preserved ejection fraction

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular

Rivaroxaban Plasma Levels and Levetiracetam

Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations

The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial

Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease